Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

NCT03684642 on ClinicalTrials.gov · last registry update 2021-11-01

Stopped early, having planned 908 participants. The sponsor logged completion for 13 October 2020. Primary outcome, as filed: Change From Baseline to Week 56 in HbA1c. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Sanofi
Sponsor type: Industry
Enrollment: 908
Started: 2018-09-26
Primary completion: 2020-10-13 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change From Baseline to Week 56 in HbA1c

Conditions studied

Type 2 Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.